Darwin Wealth Management’s Fortune Brands Innovations FBIN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$50.5K Buy
920
+6
+0.7% +$240 0.01% 232
2026
Q1
$35.6K Buy
914
+5
+0.6% +$260 0.01% 248
2025
Q4
$45.5K Buy
909
+2
+0.2% +$100 0.01% 224
2025
Q3
$48.4K Buy
907
+2
+0.2% +$113 0.02% 221
2025
Q2
$46.6K Buy
905
+4
+0.4% +$209 0.02% 212
2025
Q1
$61.6K Hold
901
0.02% 206
2024
Q4
$61.6K Buy
901
+1
+0.1% +$80 0.02% 206
2024
Q3
$80.6K Buy
+900
New +$69K 0.02% 203
2022
Q1
Sell
-2,621
Closed -$216K 172
2021
Q4
$216K Hold
2,621
0.03% 161
2021
Q3
$200K Hold
2,621
0.03% 166
2021
Q2
$223K Hold
2,621
0.04% 163
2021
Q1
$214K Buy
+2,621
New +$198K 0.04% 155
2020
Q2
Sell
-2,621
Closed -$96K 344
2020
Q1
$96K Buy
+2,621
New +$138K 0.03% 180

Other funds holding FBIN

Darwin Wealth Management's FBIN Position: Q2 2026 in Review

Darwin Wealth Management increased its Fortune Brands Innovations (FBIN) stake by 0.66% in Q2 2026, buying an estimated $240 and bringing the position to 920 shares worth $50.5K. The position accounts for 0.01% of the portfolio, ranked #232.

Darwin Wealth Management first reported a position in FBIN in Q1 2020 and has held it in 13 quarters since. The position peaked at $223K in Q2 2021. 528 funds tracked by Wall St. Rank hold FBIN as of Q2 2026.

  • Darwin Wealth Management held 920 shares of Fortune Brands Innovations worth $50.5K as of Q2 2026.
  • Darwin Wealth Management bought 6 Fortune Brands Innovations shares in Q2 2026, an estimated $240.
  • Fortune Brands Innovations made up 0.01% of Darwin Wealth Management's portfolio in Q2 2026, its #232 holding.
  • Darwin Wealth Management first reported a position in Fortune Brands Innovations in Q1 2020 and has held it in 13 quarters since.
  • Darwin Wealth Management's Fortune Brands Innovations position peaked at $223K in Q2 2021.
  • 528 funds tracked by Wall St. Rank held Fortune Brands Innovations as of Q2 2026.

Based on Darwin Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.